Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Veterinary Medicine, Infectious Diseases, Oncology +17

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Reinhard Kirnbauer, Frank P. Booy, N. Cheng et al. · Proceedings of the National Academy of Sciences · 1992 · 1.1K citations

Life Sciences, Immunology, Molecular Biology +17

Against which human papillomavirus types shall we vaccinate and screen? the international perspective

Núbia Muñóz, F. Xavier Bosch, Xavier Castellsagué et al. · International Journal of Cancer · 2004 · 1.1K citations · Full text

Medicine, Infectious Diseases, Oncology +17

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

JoAnn Suzich, S. Ghim, Frances J. Palmer‐Hill et al. · Proceedings of the National Academy of Sciences · 1995 · 671 citations

Life Sciences, Immunology, Infectious Diseases +17